Celgene Header

body {background: #000; font-family: Arial, Helvetica, sans-serif; font-size: 12px; color: #FFF; text-align: left; margin-top: 50px;}#wrapper-celgene {border: 1px solid #9c9c9c; width: 965px; padding-bottom: 20px; overflow: hidden; background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/background-celgene.png); background-repeat:repeat-y;}#cn {font-size: 12px; font-weight: bold; margin-bottom: 10px;}#header {margin-left: 25px;}#footer {font-size: 10px; margin-top: 10px;}#wrapper-content {margin: 5px 0 10px 25px;}#panel-left {width: 635px; float: left;}#panel-right {float: left; margin-left: 25px;}#slide {background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/slide-off.png);width: 265px;height: 91px;margin-bottom: 7px;}#slide .left{width:90px; height: 90px; float: left; border: 1px solid #9c9c9c;}#slide .right{margin: 15px 0 0; float: right; width: 165px;}#slide-hot {background-image: url(http://imaging.ubmmedica.com/all/editorial/cancernetwork/infocenter/celgene/slide-on.png);width: 265px;height: 91px;margin-bottom: 7px;}#slide-hot .left{width:90px; height: 90px; float: left; border: 1px solid #9c9c9c;}#slide-hot .right{margin: 15px 0 0; float: right; width: 165px;}a {color: #fff;}


Return to CancerNetwork

Related Videos
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
Experts on MM
Experts on colorectal cancer
Experts on MM
An expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Experts on multiple myeloma
Experts on multiple myeloma
Expert on MM
Related Content